- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06542874
제2형 당뇨병 환자의 NNC0487-0111 약물 투여량에 따라 혈당이 얼마나 낮아지는지 비교하는 연구 조사
제2형 당뇨병 참가자에 대한 주 1회 피하 및 1일 1회 경구 NNC0487-0111의 안전성 및 유효성 - 용량 찾기 연구
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
연구 개요
상태
정황
연구 유형
등록 (실제)
단계
- 2 단계
연락처 및 위치
연구 장소
-
-
-
Athens, 그리스, 115 25
- Iatriko Psychicou Private Clinic
-
Athens, 그리스, 12462
- U.G.H of Athens "Attikon"
-
Goudi/Athens, 그리스, 11527
- "Laiko" General Hospital of Athens
-
Thessaloniki, 그리스, GR-54643
- EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
-
Thessaloniki, 그리스, GR-57001
- "Thermi" Private Hosital
-
Thessaloniki, 그리스, 564 29
- 424 Military General Training Hospital
-
Thessaloniki, 그리스, 57001
- "Thermi" Private Hosital
-
Thessaloniki, 그리스, 54645
- EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
-
Thessaloniki, 그리스, 564 29
- 424 Military General Training Hospital - 2nd Department of Internal Medicine
-
-
-
-
-
Elsterwerda, 독일, 04910
- Zentrum für klinische Studien Südbrandenburg GmbH
-
Elsterwerda, 독일, 04910
- Zentrum fuer klinische Studien Suedbrandenburg GmbH
-
Essen, 독일, 45136
- InnoDiab Forschung GmbH
-
Hamburg, 독일, 22607
- Wendisch/Dahl Hamburg
-
Hamburg, 독일, 22607
- Wendisch - Dahl Hamburg - DZHW
-
Münster, 독일, 48145
- Institut für Diabetesforschung GmbH Münster - Dr. med. Rose
-
Oldenburg in Holstein, 독일, 23758
- RED-Institut für medizinische Forschung und Fortbildung GmbH
-
-
-
-
-
Brasov, 루마니아, 500101
- Mariodiab Clinic SRL
-
Timișoara, 루마니아, 300723
- Spitalul Clinic Judetean De Urgenta Pius Brinzeu Timisoara
-
Timișoara, 루마니아, 300288
- Cabinet Medical Dr Geru SRL
-
-
Bihor County
-
Oradea, Bihor County, 루마니아, 410025
- SC Grand Med SRL
-
Oradea, Bihor County, 루마니아, 410159
- Grandmed SRL
-
-
Bucharest
-
Bucharest, Bucharest, 루마니아, 020475
- Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
-
-
Bucurestii
-
Bucharest, Bucurestii, 루마니아, 020475
- Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
-
-
Cluj
-
Cluj-Napoca, Cluj, 루마니아, 400006
- Spitalul Clinic Judetean Urgenta Cluj-Napoca
-
-
Mureș County
-
Târgu Mureş, Mureș County, 루마니아, 540142
- Sc Mediab Srl
-
-
Prahova
-
Ploieşti, Prahova, 루마니아, 100018
- Novus Medical Clinica SRL
-
-
-
-
Alabama
-
Birmingham, Alabama, 미국, 35294
- Uni of Alabama at Birmingham
-
-
California
-
Los Angeles, California, 미국, 90057
- Velocity Clin Research LA
-
Santa Ana, California, 미국, 92701
- Southern Cal Clinical Research
-
-
Connecticut
-
Waterbury, Connecticut, 미국, 06708
- Chase Medical Research LLC
-
-
Florida
-
Fleming Island, Florida, 미국, 32003
- Fleming Island Ctr for Clin Res
-
Hollywood, Florida, 미국, 33024
- Encore Medical Research LLC
-
Miramar, Florida, 미국, 33027
- South Broward Research LLC
-
Orlando, Florida, 미국, 32825
- Florida Inst For Clin Res
-
Orlando, Florida, 미국, 32825
- Florida Institute for Clinical research
-
-
Illinois
-
Chicago, Illinois, 미국, 60607
- Cedar-Crosse Research Center
-
-
Kansas
-
Topeka, Kansas, 미국, 66606
- Cotton O'Neil Clinical Research Center
-
-
Kentucky
-
Paducah, Kentucky, 미국, 42001
- Advanced Internal Medicine, PLLC
-
-
Maryland
-
Hyattsville, Maryland, 미국, 20782
- Medstar Research Institute_Hyattsville
-
Oxon Hill, Maryland, 미국, 20745
- MD Medical Research
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- Brigham & Women's Hospital
-
Methuen, Massachusetts, 미국, 01844
- ActivMed Practice & Research LLC
-
-
Michigan
-
Troy, Michigan, 미국, 48098
- Arcturus Healthcare, PLC
-
Troy, Michigan, 미국, 48098
- Arcturus HC PLC Troy Med Res
-
-
Missouri
-
Chesterfield, Missouri, 미국, 63005
- Clinical Research Professionals
-
City of Saint Peters, Missouri, 미국, 63303
- StudyMetrix Research LLC
-
-
New York
-
Albany, New York, 미국, 12203
- AMC Community Endocrinology
-
-
North Carolina
-
Morehead City, North Carolina, 미국, 28557
- Centricity Rsrch MHCity Multi
-
Statesville, North Carolina, 미국, 28625
- Piedmont Healthcare/Research
-
-
North Dakota
-
Fargo, North Dakota, 미국, 58104
- Lillestol Research LLC
-
Fargo, North Dakota, 미국, 58104
- Plains Clinical Research Center, LLC_Fargo
-
-
Oklahoma
-
Norman, Oklahoma, 미국, 73069
- Alliance for Multispec Res
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19107-6810
- Jefferson Endocrinology Assocs
-
Pittsburgh, Pennsylvania, 미국, 15236
- Preferred Primary Care Physicians_Pittsburgh
-
-
South Dakota
-
Rapid City, South Dakota, 미국, 57702
- Health Concepts
-
-
Tennessee
-
Kingsport, Tennessee, 미국, 37660
- Holston Medical Group
-
Nashville, Tennessee, 미국, 37203
- Clinical Research Associates
-
Nashville, Tennessee, 미국, 37203
- MidState Endocrine Associates
-
-
Texas
-
Dallas, Texas, 미국, 75230
- Velocity Clinical Res-Dallas
-
Houston, Texas, 미국, 77024
- Victorium Clinical Research
-
Houston, Texas, 미국, 77079
- PlanIt Research, PLLC
-
Houston, Texas, 미국, 77061
- Synergy Groups Medical
-
Lampasas, Texas, 미국, 76550
- Radiance Clinical Research
-
McKinney, Texas, 미국, 75069
- Tekton Research
-
Waco, Texas, 미국, 76708
- Hillcrest Family Health Center
-
-
-
-
-
Kyustendil, 불가리아, 2500
- Individual Practice For Specialized Outpatient Medical Care Doctor Miglena Rizova Ltd.
-
Kyustendil, 불가리아, 2500
- IPSOMC Dr. Miglena Rizova Ltd.
-
Plovdiv, 불가리아, 4002
- DCC Sveti Georgi EOOD
-
Plovdiv, 불가리아, 4001
- UMHAT "Kaspela", Depart. Endocrinology and Metab. Diseases
-
Plovdiv, 불가리아, 4002
- Diagnostic-Consultative Centre "Sveti Georgi" Eood
-
Plovdiv, 불가리아, 4001
- UMHAT Kaspela EOOD, Endocrinology and Metabolic Diseases Clinic
-
Sofia, 불가리아, 1431
- USHATE "Akad. Ivan Penchev" Second Clinic of Endocrinology
-
Sofia, 불가리아, 1431
- UMHAT "Aleksandrovska"
-
Sofia, 불가리아, 1000
- Medical centre Regina Life Clinic EOOD
-
Sofia, 불가리아, 1431
- USHATE Akad. Ivan Penchev EAD, Second Clinic of Endocrinology
-
Sofia, 불가리아, 1431
- UMHAT Aleksandrovska EAD, Densitometry and Bone Metabolic Diseases
-
Varna, 불가리아, 9020
- AIPSMC Dr. Artin Magardichyan EOOD
-
-
-
-
-
A Coruña, 스페인, 15006
- Complejo Hospitalario Universitario A Coruña
-
Barcelona, 스페인, 08036
- Hospital Clinic i Provincial
-
Castilleja de la Cuesta, 스페인, 41950
- Hospital Vithas Sevilla
-
Madrid, 스페인, 28007
- Hospital Gregorio Marañón
-
Pontevedra, 스페인
- Complejo Hospitalario de Pontevedra - Hospital de Montecelo
-
Santander, 스페인, 39008
- Hospital Universitario Marqués de Valdecilla
-
Seville, 스페인, 41003
- Clínica Nuevas Tecnologías en Diabetes y Endocrinología
-
Seville, 스페인, 41010
- Hospital Infanta Luisa
-
Seville, 스페인, 41950
- Hospital Nisa Sevilla Aljarafe
-
Seville, 스페인, 41010
- H. Infanta Luisa_Endocrino y Obesidad
-
-
-
-
-
Poprad, 슬로바키아, 05801
- DENTAVIA s.r.o.
-
Prešov, 슬로바키아, 080 01
- DIABETOL, s.r.o.
-
Rimavská Sobota, 슬로바키아, 979 01
- OLIVER - MED s.r.o.
-
Žilina, 슬로바키아, 010 01
- MEDIVASA, s.r.o., Diabetologicka ambulancia
-
-
Slovak Republic
-
Šahy, Slovak Republic, 슬로바키아, 93601
- Peter Farkas MD, s.r.o.
-
-
-
-
-
Aichi, 일본, 468-0009
- TOSAKI Clinic for Diabetes and Endocrinology_Diabetes and Endocrinology
-
Chiba, 일본, 261-0004
- Tokuyama clinic_Diabetic internal medicine
-
Chiba, 일본, 261-0004
- Tokuyama clinic
-
Chiba-shi, Chiba, 일본, 260-0804
- Akaicho Clinic
-
Ibaraki, 일본, 311-0113
- Naka Kinen Clinic
-
Ibaraki, 일본, 311-0113
- Naka Kinen Clinic_Internal medicine
-
Tokyo, 일본, 103-0027
- Tokyo-Eki Center-building Clinic
-
Tokyo, 일본, 104-0031
- Fukuwa Clinic
-
Tokyo, 일본, 103-0027
- Tokyo-Eki Center-building Clinic_Internal Medicine
-
Tokyo, 일본, 104-0031
- Fukuwa Clinic_Internal Medicine
-
-
Miyazaki
-
Miyazaki, Miyazaki, 일본, 880-0034
- Heiwadai Hospital_Internal Medicine
-
Miyazaki, Miyazaki, 일본, 880-0034
- Heiwadai Hospital
-
-
-
-
-
Karlovac, 크로아티아, 47000
- Opca bolnica Karlovac
-
Krapinske Toplice, 크로아티아, 49217
- Specijalna bolnica Krapinske Toplice - Endokrinologija
-
Krapinske Toplice, 크로아티아, 49217
- Specijalna Bolnica za medicinsku rehabilitaciju Krapinske Toplice_Endocrinology
-
Osijek, 크로아티아, 31 000
- Klinicki bolnicki centar Osijek_Endocrinology
-
Osijek, 크로아티아, 31 000
- Klinicki bolnicki centar Osijek
-
Varaždin, 크로아티아, 42 000
- Opca bolnica Varazdin_Endocrinology
-
Varaždin, 크로아티아, 42 000
- Opca bolnica Varazdin
-
-
City of Zagreb
-
Zagreb, City of Zagreb, 크로아티아, 10000
- Poliklinika Solmed
-
-
Primorje-Gorski Kotar County
-
Rijeka, Primorje-Gorski Kotar County, 크로아티아, 51 000
- KBC Rijeka, Endokrinologija
-
Rijeka, Primorje-Gorski Kotar County, 크로아티아, 51 000
- Clinical Hospital Centre Rijeka_Endocrinology
-
-
-
-
-
Bialystok, 폴란드, 15-375
- Specderm Poznańska Spółka Jawna
-
Lublin, 폴란드, 20-718
- EKAMED sp. z o.o.
-
Ruda Śląska, 폴란드, 41-709
- Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
-
Warsaw, 폴란드, 02-507
- PANSTWOWY INSTYTUT MEDYCZNY MSWiA
-
-
Gornoslaskie
-
Ruda Śląska, Gornoslaskie, 폴란드, 41-709
- Niepubliczny Zaklad Opieki Zdrowotnej Przychodnia Specjalistyczna A Wittek H Rudzki Sp. j.
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, 폴란드, 31-261
- Med. Cent. Diabet. Endo. Metabol. DIAB-ENDO-MET
-
Oświęcim, Lesser Poland Voivodeship, 폴란드, 32-600
- Formed 2 Sp. z o.o.
-
-
Lower Silesian Voivodeship
-
Legnica, Lower Silesian Voivodeship, 폴란드, 59-220
- Beata Mikłaszewicz & Dariusz Dąbrowski "CARDIAMED" s.j.
-
Legnica, Lower Silesian Voivodeship, 폴란드, 59-220
- Beata Miklaszewicz & Dariusz Dabrowski "CARDIAMED" s.j.
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, 폴란드, 20-718
- EKAMED sp. z o.o.
-
-
Masovian Voivodeship
-
Siedlce, Masovian Voivodeship, 폴란드, 08-110
- ETG Siedlce
-
-
Podlaskie Voivodeship
-
Bialystok, Podlaskie Voivodeship, 폴란드, 15-879
- NZOZ Vita-Diabetica Malgorzata Buraczyk
-
Bialystok, Podlaskie Voivodeship, 폴란드, 15-375
- Specderm Poznanska Sp. j.
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, 폴란드, 90-302
- Santa Sp. z o.o, Santa Familia Centrum Badan, Profilaktyki i Leczenia
-
-
-
-
-
Budapest, 헝가리, 1106
- Bajcsy-Zsilinszky Kórház
-
Budapest, 헝가리, 1134
- MH Egészségügyi Központ
-
Debrecen, 헝가리, 4031
- Debreceni Egyetem
-
Debrecen, 헝가리, H-4031
- Debreceni Egyetem
-
Debrecen, 헝가리, H-4032
- Debreceni Egyetem
-
Gyula, 헝가리, 5700
- Békés Megyei Központi Kórház
-
Kaposvár, 헝가리, 7400
- Somogy Vármegyei Kaposi Mór Oktató Kórház
-
Kaposvár, 헝가리, H-7400
- Somogy Vármegyei Kaposi Mór Oktató Kórház
-
-
Hajdú-Bihar
-
Debrecen, Hajdú-Bihar, 헝가리, 4032
- Debreceni Egyetem
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male or female, aged 18-75 years (both inclusive) at the time of signing the informed consent.
- Diagnosed with type 2 diabetes mellitus greater or equal to 180 days before screening.
- Stable daily dose(s) greater or equal to 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator: metformin with or without SGLT2 inhibitor.
- HbA1c of 7.0-10.0 procent (53-86 mmol/mol) (both inclusive) as assessed by central laboratory at screening.
- Body mass index between greater or equal to 23.0 and below 50.0 kg/m^2.
- Able and willing to adhere to the protocol including wearing a continuous glucose monitoring (CGM) device provided for the study, as judged by the investigator.
Exclusion Criteria:
- Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
- Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: Placebo subcutaneous
Placebo for subcutaneous treatment |
NNC0487-0111 placebo administered subcutanously (under the skin) |
|
실험적: NNC0487-0111 subcutaneous dose 1
NNC0487-0111 subcutaneous dose 1 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
실험적: NNC0487-0111 subcutaneous dose 2
NNC0487-0111 subcutaneous dose 2 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
실험적: NNC0487-0111 subcutaneous dose 3
NNC0487-0111 subcutaneous dose 3 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
실험적: NNC0487-0111 subcutaneous dose 4
NNC0487-0111 subcutaneous dose 4 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
실험적: NNC0487-0111 subcutaneous dose 5
NNC0487-0111 subcutaneous dose 5 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
실험적: NNC0487-0111 subcutaneous dose 6
NNC0487-0111 subcutaneous dose 6 treatment |
NNC0487-0111 administered subcutanously (under the skin) |
|
위약 비교기: Placebo oral
Placebo for oral treatment |
NNC0487-0111 placebo administered orally (in the mouth) |
|
실험적: NNC0487-0111 oral dose 1
NNC0487-0111 oral dose 1 treatment |
NNC0487-0111 administered orally (in the mouth) |
|
실험적: NNC0487-0111 oral dose 2
NNC0487-0111 oral dose 2 treatment |
NNC0487-0111 administered orally (in the mouth) |
|
실험적: NNC0487-0111 oral dose 3
NNC0487-0111 oral dose 3 treatment |
NNC0487-0111 administered orally (in the mouth) |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Change in HbA1c
기간: From baseline (week 0) to end of treatment (week 36)
|
percent point |
From baseline (week 0) to end of treatment (week 36)
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Relative change in body weight
기간: From baseline (week 0) to end of treatment (week 36)
|
percent |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body weight
기간: From baseline (week 0) to end of treatment (week 36)
|
kg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in fasting plasma glucose (FPG)
기간: From baseline (week 0) to end of treatment (week 36)
|
mmol/L |
From baseline (week 0) to end of treatment (week 36)
|
|
CGM: Change in time in range (TIR) 3.9-10.0 mmol/L (70-180 mg/dL)
기간: From baseline (week 0) to end of treatment (week 36)
|
percent points |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in body mass index (BMI)
기간: From baseline (week 0) to end of treatment (week 36)
|
kg/m^2 |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in waist circumference
기간: From baseline (week 0) to end of treatment (week 36)
|
cm |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in systolic blood pressure (SBP)
기간: From baseline (week 0) to end of treatment (week 36)
|
mmHg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in average 24-hour systolic blood pressure (SBP)
기간: From baseline (week 0) to end of treatment (week 36)
|
mmHg |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high sensitivity C-Reactive Protein (hsCRP)
기간: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in total cholesterol
기간: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in high-density lipoprotein (HDL) cholesterol
기간: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in low-density lipoprotein (LDL) cholesterol
기간: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Change in triglycerides
기간: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Number of adverse events
기간: From baseline (week 0) to end of study (week 40)
|
Count of events |
From baseline (week 0) to end of study (week 40)
|
|
Change in Urinary Albumin/Creatinine Ratio (UACR)
기간: From baseline (week 0) to end of treatment (week 36)
|
Ratio to baseline |
From baseline (week 0) to end of treatment (week 36)
|
|
Participant without macroalbuminuria (UACR < 300 mg/g) at baseline (week 0) developing (yes/no) new onset of macroalbuminuria (UACR ≥ 300 mg/g)
기간: At end of treatment (week 36)
|
Count of participant |
At end of treatment (week 36)
|
|
Change in eGFR creatinine- and cystatin C based CKD-EPI
기간: From baseline (week 0) to end of treatment (week 36)
|
mL/min/1.73 m^2 |
From baseline (week 0) to end of treatment (week 36)
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Clinical Transparency (dept. 2834), Novo Nordisk A/S
간행물 및 유용한 링크
일반 간행물
- Mora P, Aroda VR, Asong M, Bluher M, Heftdal LD, Carlander AF, Vilsen LN, Rosenstock J. Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01248-1. doi: 10.1016/S0140-6736(26)01248-1. Online ahead of print.
- Mora P, Aroda VR, Asong M, Bluher M, Carlander AF, Kaltoft M, Vilsen LN, Rosenstock J. Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. Lancet. 2026 Jul 30:S0140-6736(26)01247-X. doi: 10.1016/S0140-6736(26)01247-X. Online ahead of print.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- NN9490-7678
- U1111-1296-9708 (기타 식별자: World Health Organization (WHO))
- 2023-509412-28 (기타 식별자: European Medical Agency (EMA))
- 2023 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .